Wysa, a global leader in AI-driven mental health support, has acquired Kins, a U.
S. physical therapy services company. This strategic move aims to accelerate the integration of clinically proven AI solutions into established healthcare services, thereby addressing the common co-occurrence of musculoskeletal and behavioral health needs in patients.
The acquisition reflects a “reverse acquisition” strategy, where Wysa adopts healthcare services rather than waiting for healthcare to adopt AI. The objective is to enhance accessibility to care, expedite the adoption of AI innovations within existing services, and comprehensively address patients’ physical and mental health needs while maintaining clinician involvement. This approach is designed to deliver effective care beyond traditional clinic settings, directly integrating Wysa’s AI into care pathways.
Evidence for this integrated approach has been observed in various settings. For instance, Travelers insurance reported that employees with physical injuries utilizing Wysa in workers’ compensation programs returned to work one-third faster than those without AI support, highlighting the link between mental and physical recovery outcomes.
Jo Aggarwal, CEO of Wysa, stated, “There is no physical health without mental health. Bringing Wysa and Kins together is a focused step toward closing access gaps across mind and body without adding complexity for patients or clinicians.”
Ramakant Vempati, President of Wysa, added, “Rather than waiting for healthcare services to adopt AI at scale, we’re adopting healthcare services to get our clinically proven technology to patients rapidly, safely, and with clinicians leading care.”
Dan Smith, CEO of Kins, commented, “Kins exists to empower licensed clinicians to deliver effective care in the real world. Together with Wysa, we will move faster on the problems that patients and providers face every day.”
Wysa’s AI technology is currently deployed with national health systems and major insurers, including the UK’s NHS Talking Therapies, Singapore’s Ministry of Health, and Vitality insurance. Its evidence base includes extensive peer-reviewed research and recognition by the FDA with a Breakthrough Device designation for an AI-led conversational CBT tool designed to address chronic pain, depression, and anxiety symptoms. Earlier this year, Wysa also acquired April Health, which focuses on integrating AI-enabled virtual behavioral health services into primary care. This latest acquisition reinforces Wysa’s commitment to combining AI innovation with human-led healthcare services to develop a new evidence base for scalable hybrid care models addressing complex patient needs.
